Born in the USA: Biotech accelerator launched in UK’s golden triangle
Nucleate, a non-profit biotech accelerator programme which has been incredibly successful across the US, is launching this side of the Atlantic and will operate within the golden triangle of London, Oxford and Cambridge.
The venture aims to run a single biotech accelerator programme this autumn to provide further support for life science entrepreneurs; to educate and empower aspiring leaders in the sector.
Nucleate says the primary aim is an educational one – giving early-stage researchers the skills, networks and resources to effectively translate their research into successful biotech startups.
Over the past four years, Nucleate has validated its flagship accelerator in 10 cities across the United States, including Boston, San Francisco, New York, and Houston.
So far, the programme has incubated 107 companies that have raised over $152 million to develop new technologies in domains including protein sequencing (Glyphic Biotechnologies), drug discovery (Manifold Bio) and microbial fertilizer (Ivu Biologics).
On the heels of its expansion in the US, Nucleate has grown into an international organisation and national teams have now been launched in Switzerland, as well as the UK, with emerging chapters incubating in countries from Israel to Japan. It plans to roll out other UK locations in the next 12 months.
“I believe that Nucleate UK has the potential to transform the biotech entrepreneurship landscape in the United Kingdom” said Miroslav Gasparek, co-Managing Director of Nucleate UK.
The UK leadership team includes Stephanie Avraamides, Director of Operations, MPhil candidate at the University of Cambridge and Abhimanyu Gowda – Director of Strategy and BA candidate at the University of Cambridge.
The organisation is now accepting early-bird applications for its inaugural, equity-free, six-month Activator program. Participants will be connected with potential co-founders, attend workshops and receive mentorship from leading academics, venture capitalists and industry-based scientists and equipped with an unparalleled network, fellowships, legal support, and other benefits.
• PHOTOGRAPH: Miroslav Gasparek. Copyright – miroslavgasparek